[Use of WOBE-MUGOS E for prevention and correction of experimental doxorubicin side-effects].
Examined in treating rats with Guerin's carcinoma with doxorubicin was the possibility that the polyenzymic drug preparation wobe-mugos E had hepatoprotective, cardioprotective and myeloprotective effects. In intramuscular administration wobe-mugos E has not been found to stimulate the tumour growth, it exhibited a manifest hepatoprotective and myeloprotective actions with respect to adverse reactions of doxorubicin but failed to diminish cardiotoxicity of the latter. The protective effect of the above polyenzymic drug was of a dose-dependent character.
Todor
I N
IN
Solianik
G I
GI
Iurchenko
O V
OV
Shpilevaia
S I
SI
Luk'ianova
N Iu
NIu
Trindiak
V P
VP
Kunskaia
L N
LN
Ponomareva
O V
OV
Terzov
A I
AI
Kulik
G I
GI
Chekhun
V F
VF
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology; D002918:Chymotrypsin / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D008099:Liver / Q000473:pathology; D008297:Male; D009206:Myocardium / Q000473:pathology; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D010206:Papain / Q000627:therapeutic use*; D020011:Protective Agents / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D014357:Trypsin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004338:Drug Combinations; D020011:Protective Agents; C009685:chymotrypsin, papain, trypsin drug combination; D004317:Doxorubicin; D002918:Chymotrypsin; D014357:Trypsin; D010206:Papain